AstraZeneca Presentation Describes The Seroquel-Diabetes Link
Drug giant AstraZeneca instructed their representatives to tell doctors that there is no link between anti-psychotic Seroquel and increased risk of diabetes, although studies by the company has already shown, by also referred to the documents found in the context of action.
AstraZeneca is the target of more than 9,000 complaints that the company hid information about the risks of Seroquel and diabetes; it was illegally marketing the drug in the “Off-label” uses that are not covered by the FDA.
Seroquel to treat schizophrenia and bipolar disorder, but also the label for the treatment of anxiety and insomnia.
If Seroquel in 1997, the label is also an indication of the risk of obesity and diabetes in the “effects” a documentary about the label, but it is not necessary, a warning about these effects. There are signs that the company knew from the outset that these two effects were more frequent and more serious than others, which occur in May, however.
In an e-mail has been found in February 1997 as part of the application, the official AstraZeneca thank you for the “big smoke and mirrors job” is to persuade the United States and Canadian regulatory authorities, that the Seroquel label test weight loss was not significant. December 1999 e-mail the publications manager complains that AstraZeneca “cherry picked” data of the study, which makes the drug seem more secure and “bury” the three studies with negative results.
In 2005, the voice mail from a company to entrust their representatives say the doctors fear that there is no participation of Seroquel as a cause of diabetes. But in 2000, the company had notice of the Government of the Netherlands recognizes that Seroquel May increase the risk of disease.
In 2003, the FDA requires that information about diabetes and weights are “side effects” of the label on the “Warning: this article. Beginning in 2009, it needs more info the risk of high blood sugar, appetite, cholesterol and weight in children and adolescents.